Received Apr 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4BX39 | — |
stated they had to receive and extra dose; This non-serious case was reported by a physician via call center representative and described the occurrence of extra dose administered in a 50-year-old female patient who received HBV (Engerix B adult) (batch number 4BX39) for prophylaxis. On 11-APR-2025, the patient received Engerix B adult. On 11-APR-2025, an unknown time after receiving Engerix B adult, the patient experienced extra dose administered (Verbatim: stated they had to receive and extra dose). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 11-APR-2025 A physician reported that about the administration of Engerix-B to a patient who previously completed a dose but was stated they had to receive and extra dose, even though they had titers present which led to extra dose administered. They also stated that the patient would probably get Heplisav and requested recommendations.